DNA methylation markers for risk of metastasis in a cohort of men with localized prostate cancer

References

• American Cancer Society. Cancer facts & statistics. 2021 [cited 2021 Sept].
   Google Scholar
• Li J, Siegel DA, King JB. Stage-specific incidence rates and trends of prostate cancer by age, race, and ethnicity, United States, 2004-2014. Ann Epidemiol. 2018 May;28(5):328–13.
   PubMed Web of Science ®Google Scholar
• Slezak JM, Den Eeden SK V, Cannavale KL, et al. Long-term follow-up of a racially and ethnically diverse population of men with localized prostate cancer who did not undergo initial active treatment. Cancer Med. 2020 Nov;9(22):8530–8539.
   PubMed Web of Science ®Google Scholar
• American Urological Association. Clinically localized prostate cancer: AUA/ASTRo/SUO guidelines. 2017 [cited 2021 Apr].
   Google Scholar
• Lam D, Clark S, Stirzaker C, et al. Advances in prognostic methylation biomarkers for prostate cancer.Cancers (Basel). 2020 Oct 15;12(10):2993. doi: 10.3390/cancers12102993
   PubMed Web of Science ®Google Scholar
• Rodenhiser DI. Epigenetic contributions to cancer metastasis. Clin Exp Metastasis. 2009;26(1):5–18.
   PubMed Web of Science ®Google Scholar
• Huynh KT, Hoon DS. Epigenetics of regional lymph node metastasis in solid tumors. Clin Exp Metastasis. 2012;29(7):747–756.
   PubMed Web of Science ®Google Scholar
• Cooper CS, Foster CS. Concepts of epigenetics in prostate cancer development. Br J Cancer. 2009;100(2):240–245.
   PubMed Web of Science ®Google Scholar
• Newell-Price J, Clark AJ, King P. DNA methylation and silencing of gene expression. Trends Endocrinol Metab. 2000;11(4):142–148.
   PubMed Web of Science ®Google Scholar
• Li Q, Chen H. Epigenetic modifications of metastasis suppressor genes in colon cancer metastasis. Epigenetics. 2011 Jul;6(7):849–852.
   PubMed Web of Science ®Google Scholar
• Shames DS, Minna JD, Gazdar AF. DNA methylation in health, disease, and cancer. Curr Mol Med. 2007;7:85–102.
   PubMed Web of Science ®Google Scholar
• Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med. 2011;17(3):313–319.
   PubMed Web of Science ®Google Scholar
• Okamoto OK. Cancer stem cell genomics: the quest for early markers of malignant progression. Expert Rev Mol Diagn. 2009;9(6):545–554.
   PubMed Web of Science ®Google Scholar
• Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and caner stem cells. Nature. 2001;414(6859):6859):105–11.
   Web of Science ®Google Scholar
• Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008;8(10):755–768.
   PubMed Web of Science ®Google Scholar
• Hermann PC, Huber SL, Herrler T, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell. 2007;1(3):313–323. doi: 10.1016/j.stem.2007.06.002
   PubMed Web of Science ®Google Scholar
• Klarmann GJ, Hurt EM, Mathews LA, et al. Invasive prostate cancer cells are tumor initiating cells that have a stem cell-like genomic signature. Clin Exp Metastasis. 2009;26(5):433–446. doi: 10.1007/s10585-009-9242-2
   PubMed Web of Science ®Google Scholar
• Glinsky GV. “Stemness” genomics law governs clinical behavior of human cancer: implications for decision making in disease management. J Clin Oncol. 2008;26(17):2846–2853.
   PubMed Web of Science ®Google Scholar
• Schoenhals M, Kassambara A, De Vos J, et al. Embryonic stem cell markers expression in cancers.Biochem Biophys Res Commun. 2009 May 29;383(2):157–162. doi: 10.1016/j.bbrc.2009.02.156
   PubMed Web of Science ®Google Scholar
• Colombel M, Eaton CL, Hamdy F, et al. increased expression of putative cancer stem cell markers in primary prostate cancer is associated with progression of bone metastases. Prostate. 2012;72(7):713–729. doi: 10.1002/pros.21473
   PubMed Web of Science ®Google Scholar
• Bastian PJ, Ellinger J, Wellmann A, et al. Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci. Clin Cancer Res. 2005;11(11):4097–4106.
   PubMed Web of Science ®Google Scholar
• Yoon HY, Kim SK, Kim YW, et al. Combined hypermethylation of APC and GSTP1 as a molecular marker for prostate cancer: quantitative pyrosequencing analysis. J Biomol Screen. 2012;17(7):987–992.
   PubMedGoogle Scholar
• Phé V, Cussenot O, Rouprêt M. Methylated genes as potential biomarkers in prostate cancer. BJU Int. 2010;105(10):1364–1370.
   PubMed Web of Science ®Google Scholar
• Chao CR, Slezak J, Siegmund K, et al. Genome-wide methylation profiling of diagnostic tumor specimens identified DNA methylation markers associated with metastasis among men with untreated localized prostate cancer. Cancer Med. 2023 Sep;12(18):18837–18849.
   PubMed Web of Science ®Google Scholar
• Li LC. Epigenetics of prostate cancer. Front Biosci. 2007;12(8–12):3377–3397.
   PubMedGoogle Scholar
• Li Z, Wang C, Prendergast GC, et al. Cyclin D1 functions in cell migration. Cell Cycle. 2006;5(21):2440–2442.
   PubMed Web of Science ®Google Scholar
• Gyorffy B, Lanczky A, Eklund AC, et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat. 2010;123(3):725–731. doi: 10.1007/s10549-009-0674-9
   PubMed Web of Science ®Google Scholar
• Bertucci F, Birnbaum D. Distant metastasis: not out of reach any more. J Biology. 2009;8(3):28.
   PubMedGoogle Scholar
• Glinsky GV. Genomic models of metastatic cancer: functional analysis of death-fromcancer signature genes reveals aneuploid, anoikis-resistant, metastasis-enabling phenotype with altered cell cycle control and activated Polycomb Group (PcG) protein chromatin silencing pathway. Cell Cycle. 2006;5(11):1208–1216.
   PubMed Web of Science ®Google Scholar
• Ju HX, An B, Okamoto Y, et al. Distinct profiles of epigenetic evolution between colorectal cancers with and without metastasis. Am J Pathol. 2011;178(4):1835–1846. doi: 10.1016/j.ajpath.2010.12.045
   PubMed Web of Science ®Google Scholar
• Iiizumi M, Liu W, Pai SK, et al. Drug development against metastasisrelated genes and their pathways: a rationale for cancer therapy. Biochim Biophys Acta. 2008;1786(2):87–104.
   PubMed Web of Science ®Google Scholar
• Rinker-Schaeffer CW, Welch DR, Sokoloff M. Defining the biologic role of genes that regulate prostate cancer metastasis. Current Opin Urol. 2000;10(5):397–401.
   PubMedGoogle Scholar
• Hurst DR, Welch DR. Unraveling the enigmatic complexities of BRMS1-mediatedmetastasis suppression. FEBS Lett. 2011;585(20):3185–3190.
   PubMed Web of Science ®Google Scholar
• Albini A, Mirisola V, Pfeffer U. Metastasis signatures: genes regulating tumor-microenvironment interactions predict metastatic behavior. Cancer Metastasis Rev. 2008;27(1):75–83.
   PubMed Web of Science ®Google Scholar
• Keller ET, Fu Z, Brennan M. The biology of a prostate cancer metastasis suppressor protein: raf kinase inhibitor protein. J Cell Biochem. 2005;94(2):273–278.
   PubMed Web of Science ®Google Scholar
• Chang YW, Bean RR, Jakobi R. Targeting RhoA/Rho kinase and p21-activated kinase signaling to prevent cancer development and progression. Recent Pat Anticancer Drug Discov. 2009;4(2):110–124.
   PubMed Web of Science ®Google Scholar
• Henrique R, Ribeiro FR, Fonseca D, et al. High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients. Clin Cancer Res. 2007;13(20):6122–6129. doi: 10.1158/1078-0432.CCR-07-1042
   PubMed Web of Science ®Google Scholar
• Rosenbaum E, Hoque MO, Cohen Y, et al. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy. Clin Cancer Res. 2005;11(23):8321–8325. doi: 10.1158/1078-0432.CCR-05-1183
   PubMed Web of Science ®Google Scholar
• Braga EA, Kashuba M VI, AV L VI, et al. New tumor suppressor genes in hot spots of human chromosome 3: new methods of identification. Mol Biol. 2003;37(2):194–211. doi: 10.1023/A:1023381218481
   Web of Science ®Google Scholar
• Zlobec I, Minoo P, Baker K, et al. Loss of APAF-1 expression is associated with tumour progression and adverse prognosis in colorectal cancer. Eur J Cancer. 2007;43(6):1101–1107. doi: 10.1016/j.ejca.2007.01.029
   PubMed Web of Science ®Google Scholar
• Mehta HH, Gao Q, Galet C, et al. IGFBP-3 is a metastasis suppression gene in prostate cancer. Cancer Res. 2011;71(15):5154–5163. doi: 10.1158/0008-5472.CAN-10-4513
   PubMed Web of Science ®Google Scholar
• Min Y, Ghose S, Boelte K, et al. C/EBP-delta regulates VEGF-C autocrine signaling in lymphangiogenesis and metastasis of lung cancer through HIF-1alpha. Oncogene. 2011;30(49):4901–4909.
   PubMed Web of Science ®Google Scholar
• Martin P, Liu YN, Pierce R, et al. Prostate epithelial Pten/TP53 loss leads to transformation of multipotential progenitors and epithelial to mesenchymal transition. Am J Pathol. 2011 Jul;179(1):422–435.
   PubMed Web of Science ®Google Scholar
• Bailey CL, Kelly P, Casey PJ. Activation of Rap1 promotes prostate cancer metastasis. Cancer Res. 2009;69(12):4962–4968.
   PubMed Web of Science ®Google Scholar
• Dansen TB, Burgering BM. Unravelling the tumor-suppressive functions of FOXO proteins. Trends Cell Biol. 2008 Sep;18(9):421–429.
   PubMed Web of Science ®Google Scholar
• Thomassen M, Tan Q, Kruse TA. Gene expression meta-analysis identifies chromosomal regions and candidate genes involved in breast cancer metastasis. Breast Cancer Res Treat. 2009;113(2):239–249.
   PubMed Web of Science ®Google Scholar
• Chen L, Li H, Liu W, et al. Olfactomedin 4 suppresses prostate cancer cell growth and metastasis via negative interaction with cathepsin D and SDF-1. Carcinogenesis. 2011;32(7):986–994. doi: 10.1093/carcin/bgr065
   PubMed Web of Science ®Google Scholar
• Iwakuma T, Agarwal N. MDM2 binding protein, a novel metastasis suppressor. Cancer Metastasis Rev. 2012 Dec;31(3–4):633–640.
   PubMed Web of Science ®Google Scholar
• Revelos K, Petraki C, Gregorakis A, et al. Immunohistochemical expression of Bcl2 is an independent predictor of time-to-biochemical failure in patients with clinically localized prostate cancer following radical prostatectomy. Anticancer Res. 2005;25(4):3123–3133.
   PubMed Web of Science ®Google Scholar
• Pinto AE, Andre S, Silva G, et al. BCL-6 oncoprotein in breast cancer: loss of expression in disease progression. Pathobiology. 2009;76(5):235–242.
   PubMed Web of Science ®Google Scholar
• Grubb RL, Deng J, Pinto PA, et al. Pathway biomarker profiling of localized and metastatic human prostate cancer reveal metastatic and prognostic signatures. J Proteome Res. 2009;8(6):3044–3054.
   PubMed Web of Science ®Google Scholar
• Fingleton B. Molecular targets in metastasis: lessons from genomic approaches. Cancer Genomics Proteomics. 2007;4(3):211–221.
   PubMedGoogle Scholar
• Gopalkrishnan RV, Kang DC, Fisher PB. Molecular markers and determinants of prostate cancer metastasis. J Cell Physio. 2001;189(3):245–256.
   PubMed Web of Science ®Google Scholar
• Nicolson GL, Nawa A, Toh Y, et al. Tumor metastasis associated human MTA1 gene and its MTA1 protein product: role in epithelial cancer cell invasion, proliferation and nuclear regulation. Clin Exp Metastasis. 2003;20(1):19–24.
   PubMed Web of Science ®Google Scholar
• Yoshida BA, Chekmareva MA, Wharam JF, et al. Prostate cancer metastasis-suppressor genes: a current perspective. Vivo. 1998;12(1):49–58.
   PubMed Web of Science ®Google Scholar
• Banez LL, Sun L, van Leenders GJ, et al. Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer. J Urol. 2010;184(1):149–156. doi: 10.1016/j.juro.2010.03.012
   PubMed Web of Science ®Google Scholar
• Weiss G, Cottrell S, Distler J, et al. DNA methylation of the PITX2 gene promoter region is a strong independent prognostic marker of biochemical recurrence in patients with prostate cancer after radical prostatectomy. J Urol. 2009;181(4):1678–1685. doi: 10.1016/j.juro.2008.11.120
   PubMed Web of Science ®Google Scholar
• Hance MW, Dole K, Gopal U, et al. Secreted Hsp90 is a novel regulator of the epithelial to mesenchymal transition (EMT) in prostate cancer. J Biol Chem. 2012;287(45):37732–37744.
   PubMed Web of Science ®Google Scholar
• Teng Y, Ngoka L, Mei Y, et al. HSP90 and HSP70 proteins are essential for stabilization and activation of WASF3 metastasis-promoting protein. J Biol Chem. 2012;287(13):10051–10059.
   PubMed Web of Science ®Google Scholar
• Wai Wong C, Dye DE, Coombe DR. The role of immunoglobulin superfamily cell adhesion molecules in cancer metastasis. Int J Cell Biol. 2012;2012:340296.
   PubMedGoogle Scholar
• Chen Q, Massague J. Molecular pathways: vcam-1 as a potential therapeutic target in metastasis. Clin Cancer Res. 2012;18(20):5520–5525.
   PubMed Web of Science ®Google Scholar
• TE MS, Colnaghi MI, Colnaghi MI. The 67 kDa laminin receptor as a prognostic factor in human cancer. Breast Cancer Res Treat. 1998;52(1–3):137–145.
   PubMed Web of Science ®Google Scholar
• Lu X, Kang Y. Epidermal growth factor signalling and bone metastasis. Br J Cancer. 2010;102(3):457–461.
   PubMed Web of Science ®Google Scholar
• Gravdal K, Halvorsen OJ, Haukaas SA, et al. Proliferation of immature tumor vessels is a novel marker of clinical progression in prostate cancer. Cancer Res. 2009;69(11):4708–4715.
   PubMed Web of Science ®Google Scholar
• Ghilardi G, Biondi ML, Cecchini F, et al. Vascular invasion in human breast cancer is correlated to T–>786C polymorphism of NOS3 gene. Nitric Oxide. 2003;9(2):118–122.
   PubMed Web of Science ®Google Scholar
• Das S, Tucker JA, Khullar S, et al. Hedgehog signaling in tumor cells facilitates osteoblast-enhanced osteolytic metastases. PloS One. 2012;7(3):e34374.
   PubMed Web of Science ®Google Scholar
• Larrieu-Lahargue F, Welm AL, Bouchecareilh M, et al. Blocking fibroblast growth factor receptor signaling inhibits tumor growth, lymphangiogenesis, and metastasis. PLoS One. 2012;7(6):e39540.
   PubMed Web of Science ®Google Scholar
• Tawadros T, Brown MD, Hart CA, et al. Ligand-independent activation of EphA2 by arachidonic acid induces metastasis-like behaviour in prostate cancer cells. Br J Cancer. 2012;107(10):1737–1744.
   PubMed Web of Science ®Google Scholar
• Vanella L, Di Giacomo C, Acquaviva R, et al. The DDAH/NOS pathway in human prostatic cancer cell lines: antiangiogenic effect of L-NAME. Int J Oncol. 2011;39(5):1303–1310. doi: 10.3892/ijo.2011.1107
   PubMed Web of Science ®Google Scholar
• Prud’homme GJ, Glinka Y. Neuropilins are multifunctional coreceptors involved in tumor initiation, growth, metastasis and immunity. Oncotarget. 2012;3(9):921–939.
   PubMed Web of Science ®Google Scholar
• Tsirmoula S, Dimas K, Hatziapostolou M, et al. Implications of pleiotrophin in human PC3 prostate cancer cell growth in vivo. Cancer Sci. 2012;103(10):1826–1832.
   PubMed Web of Science ®Google Scholar
• Zhang J, Patel L, Pienta KJ. CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. Cytokine Growth Factor Rev. 2010;21(1):41–48.
   PubMed Web of Science ®Google Scholar
• Yegnasubramanian S, Kowalski J, Gonzalgo ML, et al. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res. 2004;64(6):1975–1986. doi: 10.1158/0008-5472.CAN-03-3972
   PubMed Web of Science ®Google Scholar
• Woodson K, O’Reilly KJ, Ward DE, et al. CD44 and PTGS2 methylation are independent prognostic markers for biochemical recurrence among prostate cancer patients with clinically localized disease. Epigenetics. 2006;1(4):183–186. doi: 10.4161/epi.1.4.3530
   PubMed Web of Science ®Google Scholar
• Assou S, Le Carrour T, Tondeur S, et al. A meta-analysis of human embryonic stem cells transcriptome integrated into a web-based expression atlas. Stem Cells. 2007;25(4):961–973. doi: 10.1634/stemcells.2006-0352
   PubMed Web of Science ®Google Scholar
• Tj T Jr, Weisenberger DJ, Den Berg D V, et al. Low-level processing of illumina infinium DNA methylation beadarrays. Nucleic Acids Res. 2013 Apr;41(7):e90.
   PubMed Web of Science ®Google Scholar
• Mehrotra DV, Adewale AJ. Flagging clinical adverse experiences: reducing false discoveries without materially compromising power for detecting true signals.Stat Med. 2012 Aug 15;31(18):1918–1930. doi: 10.1002/sim.5310
   PubMed Web of Science ®Google Scholar
• Reinsch CH. Smoothing by Spline Functions. Numerische Math. 1967;10(1):177–183.
   Google Scholar
• Atkinson S, Armstrong L. Epigenetics in embryonic stem cells: regulation of pluripotency and differentiation. Cell Tissue Res. 2008;331(1):23–29.
   PubMed Web of Science ®Google Scholar
• Park IH, Zhao R, West JA, et al. Reprogramming of human somatic cells to pluripotency with defined factors.Nature. 2008 Jan 10;451(7175):141–146. doi: 10.1038/nature06534
   PubMed Web of Science ®Google Scholar